About Us

infuseon therapeutics, inc. was founded in 2012 by  Cleveland Clinic for the purpose of developing its patented unique therapeutic delivery device, the Cleveland Multiport Catheter™. This multiport convection-enhanced delivery catheter was designed by a neurosurgeon from Cleveland Clinic's Brain Tumor and NeuroOncology Center to more effectively deliver life-saving drugs to  patients at the site of their disease.

Parker-Hannifin Corporation, a global leader in motion and control technologies, is collaborating with infuseon to combine and enhance the medical design, development, and manufacturing expertise of the company. 
Michael A. Vogelbaum, MD, PhD image

Michael A. Vogelbaum, MD, PhD
Chief Medical Officer

Michael received a combined MD-PhD (Biomedical Engineering) from the University of Virginia. He is the co-inventor of the Cleveland Multiport Catheter and co-founder of infuseon therapeutics. Dr. Vogelbaum is an internationally known thought leader in neuro-oncology and his clinical practice focuses entirely on the neurosurgical management of patients with brain tumors.

Dr. Vogelbaum has over 15 years experience as a laboratory, translational and clinical scientist.  He has formulated and led multiple single center and multicenter clinical trials, including trials where he has held a sponsor-investigator IND.  He is also a co-Founder and Steering Committee member of the Response Assessment in NeuroOncology (RANO) working group, and he is a member of the NCI CTEP Brain Malignancy Steering Committee.

 

Gregory Frykman, MD image

Gregory Frykman, MD
Executive-in-Residence, Regulatory Advisor

Gregory Frykman, MD is a pharmaceutical and biotechnology policy analyst formerly of the Stanford Washington Research Group and the FDA. Dr. Frykman co-founded Framework Therapeutics, LLC, a pharmaceutical company focusing on the development and commercialization of sodium aluminosilicate, in 2003.  He received his medical degree and did his internship and residency in Internal Medicine at the University of Southern California Medical Center. Dr. Frykman completed a combined fellowship in Hematology and Medical Oncology at the Johns Hopkins School of Medicine and furthered his grounding in pharmaceutical product development as a recipient of the Cancer Research Training Award at the National Cancer Institute (NCI).  Following the training award, Dr. Frykman served as a Medical Officer in the Division of Oncology Drug Products, Center for Drug Evaluation and Research, FDA. He later joined the Washington Research Group, a team of policy analysts focusing on regulatory and policy issues affecting pharmaceutical and biotechnology industries.
Neema Mayhugh, PhD image

Neema Mayhugh, PhD
Business Development Officer

President and Principal of Wave Strategy, Neema Mayhugh is a healthcare innovation expert who helps health systems accelerate innovation and bridge the gap between research and product delivery. Drawing on extensive experience with industry leaders in healthcare, pharmaceuticals, consulting and research, Dr. Mayhugh partners with health care enterprises, designing and executing comprehensive strategies to take products from bench to bedside -- engaging partners, securing capital, and delivering desired outcomes, always with an eye towards ensuring the highest quality patient care, and enhancing the patient experience.
Suguna Rachakonda, PhD image

Suguna Rachakonda, PhD
Director, Commercial Development

Suguna Rachakonda has over a decade of experience in drug discovery and product development. She began her industry career at United Therapeutics working on early stage drug candidates and later at Pharmasset Inc. (acquired by Gilead Sciences) across multiple therapeutic areas. Suguna was involved with preclinical programs and leading multiple product development teams for antiviral therapeutics against HIV (Reverset & Racivir), Hepatitis B (Clevudine), and was a key contributor to Mericitabine and Sovaldi® the drug for Hepatitis C.  Suguna is a co-inventor on 12 issued patents and a co-author on 30 publications.
 
Prior to her current role, Suguna was the Director of Technology Commercialization at Kent State University leading all aspects of innovation management, commercialization and entrepreneurial activities. Suguna earned her Ph.D. in Organic Chemistry from University of Hyderabad, India. She was a post-doctoral fellow at Tulane University working in the area of nanostructured materials with applications in drug delivery. She received an MBA in Finance from Stern School of Business, NYU.


Who we are

Founded in 2012, infuseon therapeutics, inc. enables reliable therapeutic delivery to the brain via the patented Cleveland Multiport Catheter™ (CMC) system.

Contact Us

Clinicians 

infuseon therapeutics is currently seeking academic and clinical partners for studies using the Cleveland Multiport Catheter™.  Interested parties should contact Suguna Rachakonda, PhD at: 
srachakonda@infuseontherapeutics.com

Industry Partners

infuseon therapeutics is currently seeking industry partners interested in establishing strategic partnerships to deploy their agents using the Cleveland Multiport Catheter™.  Interested parties should contact Neema Mayhugh, PhD at: nmayhugh@infuseontherapeutics.com